The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > COLUMN
COLUMN
-
What Is the Best Path to Customers’ Hearts and Minds?
June 19, 2017
-
Doubling Down on Digital
May 26, 2017
-
Global Opportunities for Global Minds
April 21, 2017
-
Will Tepid Pricing Debate Only Go Full-Throttle after Golden Week Holidays?
March 30, 2017
-
Some Japanese Pharmaceutical Workers May Slowly Be Working Themselves to Death
March 17, 2017
-
The Best Recruiters Are Just a Little Paranoid
February 17, 2017
-
5 Killer Questions for HR to Ask Recruiters
January 20, 2017
-
What Pharma Can Learn from the Airline Industry
December 16, 2016
-
Near Death at Singapore General Hospital and 5 Lessons I Learnt
October 20, 2016
-
Reasons for a “Hold”
August 9, 2016
-
It’s Time for Market Access to Play a Leading Role
April 22, 2016
-
Biosimilars Are the New Black
March 25, 2016
-
Technology Provides Opportunities for Medical Device Companies
February 18, 2016
-
Don’t Accept the Offer
January 22, 2016
-
It’s Your Choice
December 18, 2015
-
Ask a Question and Shut Up
November 27, 2015
-
Recruiternomics
October 30, 2015
-
Pharma Companies in JPAC Are Searching for the Goldilocks Candidate
September 25, 2015
-
No… Your Company Is Not like a Family!
August 28, 2015
-
What’s Your Pharma Company’s Brand in Japan?
July 24, 2015
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…